NCT02450968.

Trial name or title	Dexamethasone for prophylaxis of acute mountain sickness in patients with chronic obstructive pulmonary disease travelling to altitude
Methods	Interventional
Participants	Inclusion criteria Chronic obstructive pulmonary disease (COPD), GOLD criteria grade 1 or 2 Living at low altitude (< 800m) Exclusion criteria COPD exacerbation severe COPD, GOLD grade 3 or 4 Arterial oxygen saturation < 92% at low altitude (< 800 metres) Diabetes, uncontrolled cardiovascular disease such as systemic arterial hypertension, coronary artery disease; previous stroke; pneumothorax in the last 2 months Untreated or symptomatic peptic ulcer disease, glaucoma, obstructive sleep apnoea Internal, neurologic or psychiatric disease that interferes with protocol compliance including current heavy smoking (> 20 cigarettes per day) Pregnant or nursing mothers Age minimum: 20 years old Age maximum: 75 years old Gender: both
Interventions	Drug: dexamethasone Drug: placebo
Outcomes	Acute mountain sickness, cumulative risk (time frame: day 3 at 3200 m) 6 minutes walk distance (time frame: day 2 at 3200 m) Acute mountain sickness, severity (time frame: day 1, day 2, day 3 at 3200 m) Arterial blood gases (time frame: day 2 at 3200 m) Perceived exertion (time frame: day 2 at 3200 m)
Starting date	May 2015
Contact information	Talant M Sooronbaev, MD
Notes	Recruiting